Chemistry:BI 1701963
From HandWiki
BI 1701963 is an investigational drug that blocks KRAS activation by binding to SOS1 proteins. The drug is thought to be effective in cancers with a KRAS mutation. It has been tested in clinical trials alone and in combination with adagrasib.[1][2][3]
References
- ↑ "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-08557&r=1" (in en). 23 June 2016. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-08557&r=1.
- ↑ Johnson, M.L.; Gort, E.; Pant, S.; Lolkema, M.P.; Sebastian, M.; Scheffler, M.; Hwang, J.; Dünzinger, U. et al. (September 2021). "524P A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis". Annals of Oncology 32: S591–S592. doi:10.1016/j.annonc.2021.08.1046. https://www.annalsofoncology.org/article/S0923-7534(21)03275-0/fulltext.
- ↑ Hofmann, Marco H.; Lu, Hengyu; Duenzinger, Ulrich; Gerlach, Daniel; Trapani, Francesca; Machado, Annette A.; Daniele, Joseph R.; Waizenegger, Irene et al. (1 July 2021). "Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.". Cancer Research 81 (13_Supplement): CT210–CT210. doi:10.1158/1538-7445.AM2021-CT210.
 |  |
